Amylyx Pharmaceuticals (NASDAQ: AMLX) Closed Its Upsized $500.2 Million Underwritten Public Offering as Scheduled Friday August 21, 2026, With 14,090,000 Shares of Common Stock Priced Wednesday August 19 at $35.50 per Share, Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital as Joint Book-Running Managers; The Offering Follows the Monday August 18 Phase 3 LUCIDITY Primary Endpoint Hit for Avexitide (Exendin 9-39, First-in-Class GLP-1 Receptor Antagonist Peptide) That Documented a 55% Reduction in the Composite Rate of Level 2 and Level 3 Hypoglycemic Events (P=0.000003) in Post-Bariatric Hypoglycemia; Use of Proceeds: Avexitide Commercial Launch Preparation, End-2026 NDA Submission Activities, AMX0318 (Long-Acting Follow-On) IND-Enabling Studies, and General Corporate Purposes; Underwriter 30-Day Option for Additional 2,113,500 Shares Would Bring Total Raise Capacity to Roughly $575 Million if Fully Exercised
Amylyx Pharmaceuticals (NASDAQ: AMLX) closed its upsized $500.2 million underwritten public offering as scheduled Friday August 21, 2026. Deal terms: 14,090,000 shares of common stock priced Wednesday August 19 at $35.50 per share, with Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital as joint book-running managers. The offering follows the Monday August 18 Phase 3 LUCIDITY primary endpoint hit for avexitide (exendin 9-39, first-in-class GLP-1 receptor antagonist peptide) that documented a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (p=0.000003) in post-bariatric hypoglycemia. Use of proceeds: avexitide commercial launch preparation (Q4 2026 NDA submission), broader pipeline advancement including AMX0318 (long-acting follow-on candidate identified with Gubra A/S, IND targeted 2027), and general corporate purposes. Underwriter 30-day option for additional 2,113,500 shares at the same price less underwriting discounts and commissions would bring total raise capacity to roughly $575 million if fully exercised. Amylyx also expanded its board of directors as part of the LUCIDITY-week capital markets round. The $500 million raise provides several years of operational runway to fund the avexitide launch trajectory and the second-generation AMX0318 development program targeting the same GLP-1 receptor antagonist mechanism at a longer-acting dosing format.